Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FHIT
REST API REST API
Homo sapiens
FHIT is differentially expressed in 225 experiments: 103 organism parts: kidney, ovary, ... (101 more);, 140 disease states: normal, Burkitt's lymphoma, ... (138 more);, 91 cell types 293 cell lines 20 compound treatments and 59 other conditions.
Synonyms FRA3B, AP3Aase
Orthologs FHIT (Gallus gallus)   Fhit (Mus musculus)   HNT2 (Saccharomyces cerevisiae)   FHIT_BOVIN (Bos taurus)   fhit (Danio rerio)   ENSCING00000013269 (Ciona intestinalis)   FHIT (2 of 2) (Danio rerio)   Fhit (Rattus norvegicus)   fhit (Xenopus laevis)   B6F2G5_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, protein binding, cytoplasm, bis(5'-adenosyl)-triphosphatase activity, nucleotide metabolic process, intracellular membrane-bounded organelle, nucleus, hydrolase activity, catalytic activity, DNA replication, nickel ion binding, diadenosine triphosphate catabolic process
InterPro Term Histidine_triad_HIT
UniProt Accession Q1WAB3, Q71VB2, Q194U8, P49789, Q45QG9, A2IAS9, A2IAT6, E9PBZ0
Search EB-eye ENSG00000189283
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, E-MTAB-62, ... (28 experiments)

Factor Value U/D Experiments
HL-60
2
E-MTAB-37, E-GEOD-24147
MCF-10A
2
E-GEOD-14990, E-TABM-420
MOLT4
2
E-MTAB-37, E-MTAB-62
PC3
2
E-MEXP-2034, E-GEOD-14464
SW480
2
E-MEXP-1014, E-GEOD-18005
BT474
1
2
E-MEXP-440, E-MTAB-37, E-MTAB-62
287 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-22529, E-GEOD-20193, E-GEOD-21668, E-MEXP-750, ... (46 experiments)

Factor Value U/D Experiments
human foreskin fibroblast
2
E-GEOD-18147, E-GEOD-18265
CD34+
2
E-AFMX-5, E-TABM-145
CD4+ T cell
2
3
E-AFMX-5, E-GEOD-6740, E-MEXP-1600, E-TABM-145, E-GEOD-19069 ... (5 experiments)
iPS cells from episomal vectors (Defined Factor)
1
E-GEOD-20033
CD34+CD38-/lowCD19+ cell
1
E-MEXP-1403
M1 macrophage
1
E-GEOD-5099
85 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-22529, E-GEOD-15960, E-GEOD-4045, ... (45 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-GEOD-4290, E-GEOD-6014, E-MTAB-37
adenocarcinoma
2
E-MEXP-1331, E-MTAB-62
colon carcinoma
2
E-MTAB-37, E-MTAB-62
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
134 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-15205, E-GEOD-5824, E-GEOD-15811, E-GEOD-5099, ... (16 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-1335, E-MEXP-941
none
3
4
E-MEXP-1958, E-MEXP-1230, E-GEOD-412, E-GEOD-7307, E-GEOD-5099, ... (7 experiments)
glucose
1
E-MEXP-941
interleukin-4 (Homo sapiens)
1
E-GEOD-5099
MIG control
1
E-GEOD-15811
vanadium pentoxide
1
E-GEOD-5339
14 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21374, E-GEOD-2034, E-GEOD-1563, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-MEXP-2359, E-MEXP-958, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138 ... (5 experiments)

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-TABM-868, E-GEOD-18005, E-GEOD-17347, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-20504, E-MEXP-1446, E-GEOD-22278, E-MEXP-2146, E-GEOD-20505 ... (5 experiments)

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-1926, E-MEXP-2069, ... (27 experiments)

Infection
studied in E-MEXP-561

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-TABM-84

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-1460, E-MEXP-1403

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-19069, E-GEOD-7307

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799

Treatments comments 98 240
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.432 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM